整合素的作用,一个血小板糖蛋白IIb/IIIa受体对抗剂,在不稳定的心痛. 一个随机的多中心试验
S P Schulman1, P J Goldschmidt-Clermont, E J Topol
1Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md, USA.
Circulation
|November 1, 1996
概括
与阿司匹林相比,在不稳定的心脏病患者中,整体林显著减少了缺血事件. 这种强有力的血小板抑制剂在添加氨酸治疗时耐受性良好且有效.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学 是一个学科.
背景情况:
- 阿司匹林是一种弱血小板聚合抑制剂,用于不稳定的心痛.
- 糖蛋白 (GP) IIb/IIIa抑制是抗血小板治疗的目标.
研究的目的:
- 为了评估Integrelin对不稳定性心脏病缺血的影响.
- 为了比较Integrelin与阿司匹林在治疗缺血事件中的作用.
主要方法:
- 227名不稳定的胸痛患者接受了肝素和标准治疗.
- 患者随机分配为阿司匹林加安慰剂,安慰剂阿司匹林加低剂量安慰剂,或安慰剂阿司匹林加高剂量安慰剂.
- 霍尔特监测评估了24-72小时治疗期间的缺血发作和持续时间.
主要成果:
- 高剂量因特雷林组的缺血发作较少 (0.24) 和较短 (8.41分钟).
- 阿司匹林组经历了更多 (1.0) 和更长 (26.2 分钟) 的缺血发作 (P < .05).
- 综合林显示出剂量依赖的血小板聚合抑制;没有发现反弹性缺血或增加的出血.
结论:
- 静脉注射的Integrelin是一种强效,可逆的血小板聚合抑制剂.
- 将Integrelin添加到肝素可以减少不稳定性 angina 的缺血事件.
- 在这种患者群体中,整合素耐受性良好,优于阿司匹林.
相关概念视频
Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...


